Edition:
India

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

5.90USD
10 Aug 2020
Change (% chg)

-- (--)
Prev Close
$5.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
101,245
52-wk High
$10.40
52-wk Low
$2.30

Latest Key Developments (Source: Significant Developments)

AGTC Announces Updated Development Plan For Its X-Linked Retinitis Pigmentosa Clinical Program
Wednesday, 22 Jul 2020 

July 22 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED RETINITIS PIGMENTOSA CLINICAL PROGRAM, INCLUDING Q1 2021 START OF PLANNED PHASE 2/3 TRIAL.APPLIED GENETIC TECHNOLOGIES - EXPANDING ONGOING PHASE 1/2 TRIAL IMMEDIATELY, PLANS TO DOSE ABOUT 20 PATIENTS IN TWO MASKED DOSING ARMS.APPLIED GENETIC TECHNOLOGIES CORP - COMPANY EXPECTS TO BEGIN DOSING IN Q4 2020 FOR PHASE 1/2 TRIAL.APPLIED GENETIC TECHNOLOGIES - CO'S REVISED PHASE 2/3 TRIAL DESIGN IS ALSO EXPECTED TO INCLUDE TWO MASKED ACTIVE ARMS IN ADDITION TO A CONTROL GROUP.APPLIED GENETIC TECHNOLOGIES CORP - EXPECTS TO BEGIN PHASE 2/3 TRIAL IN Q1 2021.  Full Article

AGTC Published Positive Preclinical Data That Provides Foundational Scientific Evidence For Its Ongoing Clinical Program In Patients With XLRP
Wednesday, 20 May 2020 

May 20 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA THAT PROVIDES FOUNDATIONAL SCIENTIFIC EVIDENCE FOR ITS ONGOING CLINICAL PROGRAM IN PATIENTS WITH X-LINKED RETINITIS PIGMENTOSA (XLRP).APPLIED GENETIC TECHNOLOGIES - DATA, WHICH DEMONSTRATE CO'S PROPRIETARY AAV VECTOR AND ENGINEERED RPGR CONSTRUCTS WERE WELL TOLERATED.APPLIED GENETIC TECHNOLOGIES - BOTH VECTORS WERE GENERALLY WELL TOLERATED, WITH RETINAL DETACHMENT AND INFLAMMATION OBSERVED ONLY IN HIGH DOSE GROUP.  Full Article

Applied Genetic Technologies Posts Quarterly Loss Of $0.50/Shr
Wednesday, 13 May 2020 

May 13 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES FINANCIAL RESULTS AND BUSINESS UPDATE FOR THE QUARTER ENDED MARCH 31, 2020.COMPANY ON TRACK TO PROVIDE MULTIPLE DATA READOUTS FOR XLRP AND ACHM CLINICAL PROGRAMS IN 2H 2020.COMPANY ON TRACK FOR END OF PHASE 2 MEETING IN Q2 2020.SEES MINIMAL COVID-19 IMPACT TO DATE.QTRLY LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.55 -- REFINITIV IBES DATA.  Full Article

Agtc Announces Pricing Of 6.50 Mln Common Shares At $5 Per Share
Friday, 7 Feb 2020 

Feb 6 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES PRICING OF $32,500,000 PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 6.50 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

AGTC Announces Proposed Public Offering Of Common Stock
Thursday, 6 Feb 2020 

Feb 5 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 6.00 MILLION COMMON SHARES.  Full Article

Applied Genetic Technologies Corp Files For Offering Of 6 Million Shares Of Common Stock
Thursday, 6 Feb 2020 

Feb 5 (Reuters) - Applied Genetic Technologies Corp ::APPLIED GENETIC TECHNOLOGIES CORP FILES FOR OFFERING OF 6 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Applied Genetic Technologies Corp Files For Common Stock Offering Of Up To $35.0 Million
Thursday, 30 Jan 2020 

Jan 29 (Reuters) - Applied Genetic Technologies Corp ::APPLIED GENETIC TECHNOLOGIES CORP FILES FOR COMMON STOCK OFFERING OF UP TO $35.0 MILLION - SEC FILING.  Full Article

AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial In X-Linked Retinitis Pigmentosa
Thursday, 9 Jan 2020 

Jan 9 (Reuters) - Applied Genetic Technologies Corp ::AGTC REPORTS POSITIVE SIX-MONTH DATA FROM ITS ONGOING PHASE 1/2 CLINICAL TRIAL IN X-LINKED RETINITIS PIGMENTOSA.APPLIED GENETIC TECHNOLOGIES CORP - DATA FROM X-LINKED RETINITIS PIGMENTOSA SUGGEST DURABLE, MEANINGFULLY IMPROVEMENTS IN CENTRAL VISUAL SENSITIVITY.APPLIED GENETIC TECHNOLOGIES CORP - SECONDARY DATA FROM PHASE 1/2 CLINICAL TRIAL SHOWED ENCOURAGING IMPROVEMENTS IN BEST CORRECTED VISUAL ACUITY.APPLIED GENETIC TECHNOLOGIES CORP - ALL PATIENTS DOSED CONTINUE TO DEMONSTRATE A FAVORABLE SAFETY PROFILE.APPLIED GENETIC TECHNOLOGIES CORP - PLANS TO INITIATE PIVOTAL TRIAL IN X-LINKED RETINITIS PIGMENTOSA BY END OF 2020.AGTC - REMAINS ON TRACK TO REPORT INTERIM SIX-MONTH DATA FROM DOSE ESCALATION COHORTS OF BOTH OF ITS ONGOING TRIALS IN ACHROMATOPSIA LATER IN JAN.  Full Article

AGTC And Otonomy Announce Strategic Collaboration To Develop, Commercialize Gene Therapy For Congenital Hearing Loss
Tuesday, 1 Oct 2019 

Oct 1 (Reuters) - Otonomy Inc ::AGTC AND OTONOMY ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE GENE THERAPY FOR CONGENITAL HEARING LOSS.OTONOMY INC - UNDER COLLABORATION AGREEMENT, PARTIES WILL EQUALLY SHARE PROGRAM COSTS AND PROCEEDS.  Full Article

AGTC Posts Fourth Quarter Results
Friday, 27 Sep 2019 

Sept 26 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES FINANCIAL RESULTS AND BUSINESS UPDATE FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2019.APPLIED GENETIC TECHNOLOGIES - PROMISING TOPLINE 6-MONTH DOSE ESCALATION DATA FROM ONGOING PHASE 1/2 CLINICAL TRIALS FOR X-LINKED RETINITIS PIGMENTOSA.APPLIED GENETIC TECHNOLOGIES CORP - PRELIMINARY THREE-MONTH XLRP DOSE EXPANSION DATA DEMONSTRATES IMPROVEMENT IN 50% OF CENTRALLY DOSED PATIENTS.APPLIED GENETIC TECHNOLOGIES CORP - EARLY DATA FROM BOTH ACHROMATOPSIA (ACHM) PROGRAMS INDICATE BIOLOGIC ACTIVITY.APPLIED GENETIC TECHNOLOGIES CORP - BOTH DATA SETS DEMONSTRATED A FAVORABLE SAFETY PROFILE.APPLIED GENETIC TECHNOLOGIES CORP - REVENUE WAS $0.4 MILLION FOR Q4 OF 2019.APPLIED GENETIC TECHNOLOGIES CORP - AS OF JUNE 30, 2019, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $82.0 MILLION.APPLIED GENETIC TECHNOLOGIES CORP - QTRLY LOSS PER SHARE $0.58.APPLIED GENETIC TECHNOLOGIES CORP - COMPANY EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2020 TO BE BETWEEN $30 AND $40 MILLION.  Full Article

BRIEF-Applied Genetic Enters Loan, Security Agreement With Banks, Financial Institutions

* APPLIED GENETIC TECHNOLOGIES - ON JUNE 30, ENTERED LOAN AND SECURITY AGREEMENT WITH SEVERAL BANKS AND OTHER FINANCIAL INSTITUTIONS/ENTITIES